EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

View source ↗

Summary

The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macular edema, diabetic m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Vgenfli (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.. Decision date: 14/08/2025